The OARSI histopathology initiative - recommendations for histological assessments of osteoarthritis in the rat

被引：517
|
作者：
Gerwin, N. [1 ]
Bendele, A. M. [2 ]
Glasson, S. [3 ]
Carlson, C. S. [4 ]
机构：
[1] Novartis Inst BioMed Res, Musculoskeletal Dis Area, CH-4002 Basel, Switzerland
[2] Univ Colorado, BolderBioPATH Inc, MCD Biol, Boulder, CO 80309 USA
[3] Pfizer, Cambridge, MA USA
[4] Univ Minnesota, Coll Vet Med, St Paul, MN 55108 USA
来源：
OSTEOARTHRITIS AND CARTILAGE | 2010年 / 18卷
关键词：
Score; Cartilage; Degeneration; Chondrocyte; Sectioning; Staining; CRUCIATE LIGAMENT TRANSECTION; ARTICULAR-CARTILAGE; INTRAARTICULAR INJECTION; SUBCHONDRAL BONE; KNEE-JOINTS; DOSE-RESPONSE; GROWTH-FACTOR; MODEL; DEGENERATION; MATRIX;
D O I：
10.1016/j.joca.2010.05.030
中图分类号：
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学（修复外科学）];
学科分类号：
摘要：
Objective During the development of disease-modifying osteoarthritis (OA) drugs, rat models of OA are frequently used for a first assessment of in vivo efficacy. The most efficacious compound in the rat model may then be tested in a larger animal model before entering human trials The aim of this study was to describe a histologic scoring system for use in different models of OA in rats that allows standardization and comparison of results obtained by different investigators Methods The experience of the authors with current scoring systems and the range of lesions observed in rat and human OA studies were considered in recommending this common paradigm for rat histologic scoring Considerations were made for reproducibility and ease of use for new scorers Additional scoring paradigms may be employed to further Identify specific effects of some disease-modifying drugs Results Although the described scoring system is more complex than the modified Mankin scores, which are recommended for some other species, the tenability study showed that it is easily understood and can be reproducibly used, even by Inexperienced scorers Conclusions The scoring paradigm described here has been found to be sufficiently sensitive to discriminate between treatments and to have high reproducibility Therefore we recommend its use for evaluation of different rat OA models as well as assessment of disease-modifying effects of treatments in these models (C) 2010 Osteoarthritis Research Society International Published by Elsevier Ltd All rights reserved
引用
收藏
页码：S24 / S34
页数：11
相关论文
共 50 条
  • [21] OARSI Clinical Trials Recommendations: Hand imaging in clinical trials in osteoarthritis
    Hunter, D. J.
    Arden, N.
    Cicuttini, Flavia M.
    Crema, M. D.
    Dardzinski, B.
    Duryea, J.
    Guermazi, A.
    Haugen, I. K.
    Kloppenburg, M.
    Maheu, E.
    Miller, C. G.
    Martel-Pelletier, J.
    Ochoa-Albiztegui, R. E.
    Pelletier, J. -P.
    Peterfy, C.
    Roemer, F.
    Gold, G. E.
    OSTEOARTHRITIS AND CARTILAGE, 2015, 23 (05) : 732 - 746
  • [22] OARSI Clinical Trials Recommendations: Design and conduct of implementation trials of interventions for osteoarthritis
    Allen, K. D.
    Bierma-Zeinstra, S. M. A.
    Foster, N. E.
    Golightly, Y. M.
    Hawker, G.
    OSTEOARTHRITIS AND CARTILAGE, 2015, 23 (05) : 826 - 838
  • [23] OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines
    Zhang, W.
    Moskowitz, R. W.
    Nuki, G.
    Abramson, S.
    Altman, R. D.
    Arden, N.
    Bierma-Zeinstra, S.
    Brandt, K. D.
    Croft, P.
    Doherty, M.
    Dougados, M.
    Hochberg, M.
    Hunter, D. J.
    Kwoh, K.
    Lohmander, L. S.
    Tugwell, P.
    OSTEOARTHRITIS AND CARTILAGE, 2008, 16 (02) : 137 - 162
  • [24] OARSI Clinical Trials Recommendations: Design and conduct of clinical trials for hip osteoarthritis
    Lane, N. E.
    Hochberg, M. C.
    Nevitt, M. C.
    Simon, L. S.
    Nelson, A. E.
    Doherty, M.
    Herontin, Y.
    Flechsenhar, K.
    OSTEOARTHRITIS AND CARTILAGE, 2015, 23 (05) : 761 - 771
  • [25] Summary and recommendations of the OARSI FDA osteoarthritis Assessment of Structural Change Working Group
    Conaghan, P. G.
    Hunter, D. J.
    Maillefert, J. F.
    Reichmann, W. M.
    Losina, E.
    OSTEOARTHRITIS AND CARTILAGE, 2011, 19 (05) : 606 - 610
  • [26] OARSI Clinical Trials Recommendations: Design and conduct of clinical trials for hand osteoarthritis
    Kloppenburg, M.
    Maheu, E.
    Kraus, V. B.
    Cicuttini, Flavia M.
    Doherty, M.
    Dreiser, R. -L.
    Henrotin, Y.
    Jiang, G. -L.
    Mandl, L.
    Martel-Pelletier, J.
    Nelson, A. E.
    Neogi, T.
    Pelletier, J. -P.
    Punzi, L.
    Ramonda, R.
    Simon, L. S.
    Wang, S.
    OSTEOARTHRITIS AND CARTILAGE, 2015, 23 (05) : 772 - 786
  • [27] EVALUATION OF THE ADHESION TO THE EULAR AND OARSI RECOMMENDATIONS FOR THE TREATMENT OF KNEE AND HIP OSTEOARTHRITIS IN CURRENT PRACTICE
    Van Linthoudt, D.
    OSTEOARTHRITIS AND CARTILAGE, 2010, 18 : S245 - S246
  • [28] OARSI Clinical Trials Recommendations: Design and conduct of clinical trials of rehabilitation interventions for osteoarthritis
    Fitzgerald, G. K.
    Hinman, R. S.
    Zeni, J., Jr.
    Risberg, M. A.
    Snyder-Mackler, L.
    Bennell, K. L.
    OSTEOARTHRITIS AND CARTILAGE, 2015, 23 (05) : 803 - 814
  • [29] The Inverse OARSI-OMERACT Criteria Is a Valid Indicator of the Clinical Worsening of Knee Osteoarthritis: Data From the Osteoarthritis Initiative
    Driban, Jeffrey B.
    Harkey, Matthew S.
    Price, Lori Lyn
    Lo, Grace H.
    McAlindon, Timothy E.
    JOURNAL OF RHEUMATOLOGY, 2021, 48 (03) : 442 - 446
  • [30] OARSI Clinical Trials Recommendations: Design, conduct, and reporting of clinical trials for knee osteoarthritis
    McAlindon, T. E.
    Driban, J. B.
    Henrotin, Y.
    Hunter, D. J.
    Jiang, G-L
    Skou, S. T.
    Wang, S.
    Schnitzer, T.
    OSTEOARTHRITIS AND CARTILAGE, 2015, 23 (05) : 747 - 760
12345